Cardioversion Treatment in India & UAE

Cardioversion for atrial fibrillation in India from $800. Electrical and pharmacological cardioversion at Apollo, Medanta, Fortis. 90% rhythm restoration. Expert electrophysiologists. Book now.

Estimated cost: $800 – $2,500 · Average stay: Same day – 1 day

Cardioversion is a medical procedure that restores normal sinus rhythm (the heart's natural coordinated beating pattern) in patients with atrial fibrillation (AF), atrial flutter, or other supraventricular tachycardias. When the heart's upper chambers (atria) beat in a chaotic, disorganized pattern instead of a coordinated synchronized rhythm, the result is atrial fibrillation — the most common sustained cardiac arrhythmia, affecting over 43 million people worldwide and increasing in prevalence with aging and the rising burden of hypertension, obesity, and heart failure.

Cardioversion — either electrical (DC cardioversion, or DCCV) or pharmacological (drug-induced) — delivers a synchronized electrical shock that simultaneously depolarizes all cardiac cells, allowing the normal sinus node to resume its role as the heart's natural pacemaker and restore coordinated rhythm. Electrical cardioversion is highly effective — achieving immediate sinus rhythm restoration in 70–95% of appropriate cases — and safe when performed with adequate anticoagulation and proper patient selection.

India's electrophysiology and cardiology units at Apollo Hospitals, Medanta – The Medicity, Fortis Escorts Heart Institute, Max Hospital, and Kokilaben Dhirubhai Ambani Hospital perform electrical cardioversions routinely as day-case procedures, using the latest biphasic defibrillators that achieve higher success rates with lower energy requirements than older monophasic technology. The cost of electrical cardioversion in India is $800–$2,500 for the complete procedure including brief hospital admission and post-procedure monitoring — compared to $3,000–$8,000 in the United States.

Cardioversion is the most effective treatment for restoring normal rhythm, but the fundamental challenge in AF management is maintaining sinus rhythm long-term after cardioversion — which requires antiarrhythmic drugs (flecainide, propafenone, sotalol, amiodarone, dronedarone), catheter ablation (pulmonary vein isolation), or both. Gaf Healthcare's cardiac coordinators work with patients to arrange not just the cardioversion but the comprehensive AF rhythm control strategy.

What is Cardioversion and When is it Needed?

Cardioversion targets tachyarrhythmias where normal rhythm can be restored by a well-timed synchronized shock: atrial fibrillation (AF — chaotic atrial activity at 350–600 impulses/minute, with irregular ventricular response); atrial flutter (organized atrial activity at 250–300/minute with 2:1 or variable block — usually regular pulse at 150/minute); junctional tachycardias; and ventricular tachycardia (VT) that is hemodynamically unstable.

Electrical DC Cardioversion (DCCV): A brief, precisely timed electrical shock delivered through chest electrodes (pads placed anteriorly and posteriorly or both anterolateral) synchronized to the QRS complex. Synchronization is critical — delivering the shock during the vulnerable T-wave period could induce ventricular fibrillation. The patient is under brief conscious sedation or general anesthesia (intravenous propofol or midazolam plus fentanyl). Energy: 120–200 joules (biphasic defibrillator) typically restores sinus rhythm with the first shock in AF; atrial flutter requires only 50–100 joules. If the first shock fails, escalating energy is tried.

Pharmacological (Chemical) Cardioversion: IV flecainide (in patients without structural heart disease); IV ibutilide; oral flecainide or propafenone ("pill in the pocket" for self-treatment of paroxysmal AF in selected patients); and IV amiodarone (slower onset — takes hours, used when other agents are contraindicated). Less reliable than DCCV (success rates 40–75%) but avoids the need for sedation.

Anticoagulation Before Cardioversion: AF allows blood to pool in the left atrial appendage (LAA), where clots can form — particularly during AF lasting more than 48 hours. Cardioversion can dislodge these clots, causing stroke. Before elective cardioversion, anticoagulation for 3–4 weeks (INR 2–3 for warfarin, or therapeutic DOACs — apixaban, rivaroxaban, edoxaban) eliminates organized clots. Alternatively, trans-esophageal echocardiogram (TEE) can directly visualize the LAA and — if no clot is seen — cardioversion can proceed immediately without a 3-week wait.

Who Needs Cardioversion?

Cardioversion is appropriate for: patients with symptomatic AF (palpitations, breathlessness, fatigue, reduced exercise tolerance) who are pursuing a rhythm-control strategy; first-episode AF (especially with reversible trigger — infection, alcohol, thyrotoxicosis); AF duration under 12 months (longer AF durations have lower success rates and higher recurrence after cardioversion); atrial flutter (which cardioverts easily at low energy and has a high acute success rate); and hemodynamically unstable tachycardias (urgent cardioversion without anticoagulation work-up when the arrhythmia is causing hypotension, chest pain, or pulmonary oedema).

Cardioversion is less appropriate for: chronic persistent AF of many years duration in elderly patients (very high recurrence within weeks, making the risk-benefit ratio unfavorable without concurrent ablation); patients who have failed multiple previous cardioversions without ablation; and patients with severe valvular disease or uncontrolled hyperthyroidism (treat the underlying cause first).

Adequate anticoagulation is mandatory unless the arrhythmia is acute (under 48 hours) or TEE excludes LAA clot. Patients who are not anticoagulated for AF for more than 48 hours should NOT undergo elective cardioversion without proper anticoagulation preparation.

How is DC Cardioversion Performed?

The patient arrives fasted (4–6 hours). IV access is placed. ECG monitoring is connected. Continuous oxygen saturation monitoring. Self-adhesive electrode pads are placed: one on the right upper chest below the clavicle, one on the left lateral chest at the cardiac apex — or anteroposterior placement (one anterior, one posterior).

Brief conscious sedation is administered — intravenous propofol (1–2 mg/kg) or midazolam (0.05–0.1 mg/kg) with fentanyl for analgesia. The defibrillator is set to synchronized mode (synchronization to the QRS complex is confirmed on the screen). Biphasic energy of 120–150 joules is selected for AF; 50–100 joules for flutter. The shock is delivered. The ECG is reviewed immediately — successful cardioversion shows a clear P-wave followed by QRS complex indicating sinus rhythm.

If the first shock fails to restore sinus rhythm: pad position is changed (repositioned anteroposteriorly); energy is escalated to 200 joules; up to three shocks are typically delivered. The patient recovers in 5–10 minutes from the sedation. A 12-lead ECG is obtained; the patient is observed for 2–4 hours, then discharged on antiarrhythmic medication and anticoagulation.

Procedure Steps

1. Pre-cardioversion: confirm anticoagulation adequacy (4 weeks of therapeutic anticoagulation, or TEE-guided approach to exclude LAA clot); electrolyte optimization (normal K+ and Mg2+ significantly improve success); thyroid function (hyperthyroidism impairs success).
2. Day-case admission: IV access; fasting confirmed; medication review (antiarrhythmic drug pre-loading with amiodarone or flecainide for 1–4 weeks may improve success).
3. Monitoring: continuous ECG, SpO2, blood pressure; synchronized mode confirmed on defibrillator.
4. Sedation: IV propofol or midazolam + fentanyl; ensure adequate sedation depth before shock delivery.
5. Shock delivery: synchronized biphasic shock at 120–200 J; confirm synchronization; deliver shock; review ECG.
6. If unsuccessful: reposition pads (anteroposterior); escalate energy; up to 3 shocks.
7. Recovery: monitor for 2–4 hours; ECG in sinus rhythm documented; blood pressure stable.
8. Discharge: antiarrhythmic drug prescription (to maintain sinus rhythm); anticoagulation continued for minimum 4 weeks post-cardioversion (LAA stun — mechanical dysfunction persists even after electrical cardioversion, maintaining thrombus formation risk); follow-up ECG at 1 week.

Cost Comparison Worldwide

Country — Range — Savings

--- — --- — ---

United States — $3,000 – $8,000 — Baseline

United Kingdom — $1,500 – $4,000 — ~50% savings vs. USA

India — $800 – $2,500 — Up to 75% savings vs. USA

UAE — $1,500 – $4,000 — ~55% savings vs. USA

Cardioversion packages in India include the day-case admission, cardiologist/electrophysiologist fee, sedation, defibrillator use, post-cardioversion monitoring, and discharge ECG. TEE (if required to exclude LAA clot) adds $300–$600. Antiarrhythmic medication and anticoagulation are prescribed separately. Gaf Healthcare arranges the complete AF management assessment — not just the cardioversion itself.

Recovery & Follow-up

Recovery from DC cardioversion is rapid — patients are fully alert within 10–15 minutes of the sedation. A 2–4 hour observation period confirms stable sinus rhythm and hemodynamics before discharge. Transient skin redness or mild discomfort at the shock pad sites is common and resolves within 24–48 hours. No activity restriction; return to normal activities the same day.

After cardioversion, antiarrhythmic medication to maintain sinus rhythm is prescribed. Anticoagulation continues for a minimum of 4 weeks — even in low-risk patients — because of the LAA stun phenomenon (mechanical dysfunction persisting despite electrical restoration of sinus rhythm). Long-term anticoagulation is continued if the patient has a CHA2DS2-VASc score above 1 (men) or 2 (women).

AF recurrence after cardioversion is common — 50–70% of patients recur within 12 months without ablation. Catheter ablation (pulmonary vein isolation) significantly improves sinus rhythm maintenance compared to antiarrhythmic drugs alone and should be discussed with all symptomatic AF patients who wish to maintain sinus rhythm long-term.

Recovery Tips

• Continue anticoagulation for at least 4 weeks after cardioversion — LAA stun persists even after rhythm restoration.
• Take antiarrhythmic medication exactly as prescribed — do not miss doses during the first weeks when AF recurrence risk is highest.
• Monitor your pulse daily — if irregular pulse recurs, record it (with a personal pulse oximeter or Apple Watch/Kardia ECG) and report promptly.
• Avoid alcohol and caffeine in the first month — both are common AF triggers.
• Maintain healthy weight and treat sleep apnoea — both are strongly associated with AF recurrence.
• Discuss catheter ablation (pulmonary vein isolation) with your cardiologist if cardioversion-maintained sinus rhythm is the long-term goal.

Risks & Complications

Cardioversion is a very safe procedure. The main risks are: stroke from dislodged LAA clot (less than 1% with adequate anticoagulation; higher without); skin burns at pad sites (very rare with modern self-adhesive pads); brief arrhythmias immediately after the shock (usually transient — spontaneous termination); and sedation risks (aspiration, hypotension — minimized by fasting and experienced anesthetist). The success rate of a single shock in converting AF to sinus rhythm is 70–95%; some cases require multiple shocks or remain in AF (refractory AF requiring re-cardioversion or ablation).

Why GAF Healthcare

Gaf Healthcare coordinates AF management programs in India and the UAE — from cardioversion through to catheter ablation for patients who want long-term sinus rhythm. We review your AF history, echo, ECG, and anticoagulation status before recommending cardioversion timing and the appropriate antiarrhythmic strategy. Our cardiac coordinators ensure anticoagulation preparation is complete before the procedure and arrange post-cardioversion follow-up.

Frequently Asked Questions

Is cardioversion painful?

No — cardioversion is performed under brief conscious sedation. You are asleep when the shock is delivered and wake up 10–15 minutes afterward with no memory of the procedure. Mild skin redness at the pad sites is the most common after-effect.

How long does cardioversion take?

The procedure itself takes 15–30 minutes. Total day-case stay including preparation and post-procedure observation is 3–5 hours. Discharge is on the same day for elective cases.

Will AF come back after cardioversion?

AF recurs in 50–70% of patients within 12 months after cardioversion without additional treatment. Antiarrhythmic medication reduces recurrence. Catheter ablation (pulmonary vein isolation) is the most effective treatment for maintaining long-term sinus rhythm and should be discussed if cardioversion alone is not sustaining rhythm.

What is the cost of cardioversion in India?

DC cardioversion costs $800–$2,500 in India all-inclusive, compared to $3,000–$8,000 in the USA. TEE (to exclude left atrial appendage clot before cardioversion) adds $300–$600.